Outcomes for the first four lines of therapy in patients with HER2-positive advanced breast cancer: results from the SONABRE registry.

Autor: Ibragimova KIE; Department of Medical Oncology, GROW, School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, PO BOX 5800, 6202 AZ, Maastricht, the Netherlands., Geurts SME; Department of Medical Oncology, GROW, School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, PO BOX 5800, 6202 AZ, Maastricht, the Netherlands., Meegdes M; Department of Medical Oncology, GROW, School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, PO BOX 5800, 6202 AZ, Maastricht, the Netherlands., Erdkamp F; Department of Internal Medicine, Zuyderland Medical Center, Sittard-Geleen, the Netherlands., Heijns JB; Department of Medical Oncology, Amphia, Breda, the Netherlands., Tol J; Department of Medical Oncology, Jeroen Bosch Hospital, Den Bosch, the Netherlands., Vriens BEPJ; Department of Internal Medicine, Catharina Hospital, Eindhoven, the Netherlands., Dercksen MW; Department of Medical Oncology, Máxima Medical Center, Eindhoven, the Netherlands., Aaldering KNA; Department of Internal Medicine, Laurentius Hospital, Roermond, the Netherlands., Pepels MJAE; Department of Internal Medicine, Elkerliek Hospital, Helmond, the Netherlands., van de Winkel L; Department of Internal Medicine, St Anna Hospital, Geldrop, the Netherlands., Peters NAJB; Department of Internal Medicine, Sint Jans Gasthuis Hospital, Weert, the Netherlands., Teeuwen-Dedroog NJA; Department of Medical Oncology, GROW, School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, PO BOX 5800, 6202 AZ, Maastricht, the Netherlands., Vriens IJH; Department of Medical Oncology, GROW, School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, PO BOX 5800, 6202 AZ, Maastricht, the Netherlands., Tjan-Heijnen VCG; Department of Medical Oncology, GROW, School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, PO BOX 5800, 6202 AZ, Maastricht, the Netherlands. vcg.tjan.heijnen@mumc.nl.
Jazyk: angličtina
Zdroj: Breast cancer research and treatment [Breast Cancer Res Treat] 2023 Apr; Vol. 198 (2), pp. 239-251. Date of Electronic Publication: 2023 Jan 12.
DOI: 10.1007/s10549-022-06832-9
Abstrakt: Purpose: We assessed the systemic treatment choices and outcomes in patients diagnosed with human epidermal growth factor receptor-2-positive (HER2 +) advanced breast cancer (ABC), for the first four lines of systemic therapy and by hormone receptor (HR) status.
Methods: We identified 330 patients diagnosed with HER2 + ABC in 2013-2018 in the Southeast of The Netherlands, of whom 64% with HR + /HER2 + and 36% with HR-/HER2 + disease. Overall survival (OS) from start of therapy was calculated using the Kaplan-Meier method.
Results: In real world, 95% of patients with HR + /HER2 + and 74% of patients with HR-/HER2 + disease received systemic therapy. In HR + /HER2 + disease, use of endocrine, chemo- and HER2-targeted therapy was , respectively, 64%, 46% and 60% in first line, and 39%, 64% and 75% in fourth line. In HR-/HER2 + disease, 91-96% of patients received chemotherapy and 77-91% HER2-targeted therapy, irrespective of line of therapy. In patients with HR + /HER2 + disease, median OS was 34.9 months (95%CI:25.8-44.0) for the first line and 12.8 months (95%CI:10.7-14.9) for the fourth line. In HR-/HER2 + disease, median OS was 39.9 months (95%CI:23.9-55.8) for the first line and 15.2 months (95%CI:10.9-19.5) for the fourth line. For patients treated with first-line pertuzumab, trastuzumab plus chemotherapy, median OS was not reached at 56.0 months in HR + /HER2 + disease and 48.4 months (95%CI:32.6-64.3) in HR-/HER2 + disease.
Conclusion: Survival times for later lines of therapy are surprisingly long and justify the use of multiple lines of systemic therapy in well-selected patients with HER2 + ABC. Our real-world evidence adds valuable observations to the accumulating evidence that within HER2 + ABC, the HR status defines two distinct disease subtypes.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz: